The CKD Anemia market in 7MM offers growth opportunities due to rising diagnosed cases, unmet clinical needs, and a promising late-stage pipeline. Strategic partnerships and in-licensing could ...
Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial ...
Our kidneys perform many important functions, that include filtering blood, and keeping the body balanced. When they fail, ...
TipRanks on MSN
Akebia Therapeutics Acquires Global Rights to ADX-097
The latest announcement is out from Akebia Therapeutics ( (AKBA) ).
Akebia Therapeutics has struck a deal for Q32 Bio’s deprioritized complement | Akebia Therapeutics has struck a deal for Q32 ...
Q: I’m 68 and overweight by 45 pounds. Now that GLP-1s are going to be covered by Medicare, I think I will add that to my ...
Artificial intelligence-enabled electrocardiography from scientific research to clinical application
Recent advancements in artificial intelligence (AI) have revolutionized the application of electrocardiography (ECG) in ...
Kidney diseases have become a major global public health problem. Contemporary populations are exposed to a constellation of clinical risk factors, acting ...
Akebia Therapeutics (AKBA) announced the establishment of its rare kidney disease pipeline. The pipeline is comprised of two core product ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback